McKesson: The Healthcare Supplier On My Buy List This Summer, As Growth Accelerates

McKesson (MCK) is rated a Buy, citing robust top-line and EPS growth plus dividend potential. The article highlights investment support from its diversified oncology exposure, partnerships with large pharma (e.g., AbbVie), and an investment-grade Fitch rating, even noting negative equity. Valuation is framed as attractive at ~18x forward earnings multiple, implying an estimated 18–22% upside by March 2028.

Analysis

MCK screens like a quality compounder, but the real edge is that its cash generation is tied to non-discretionary healthcare throughput rather than elastic end-demand. That makes the name less sensitive to macro slowing than most “value” compounds, and more resilient if bond yields stay elevated because the market can underwrite buybacks/dividend growth with visible operating cash flow rather than terminal multiple expansion.

The competitive dynamic matters more than the headline multiple. In distribution and oncology-adjacent services, scale and embedded pharma relationships create a widening moat: larger players can absorb lower spread capture and still defend share, while smaller intermediaries face margin squeeze if pricing tightens or service requirements rise. AbbVie exposure is best viewed as channel validation, not a direct earnings lever; the second-order winner is the integrated distributor/platform that can bundle logistics, specialty handling, and data services.

The main risk is that the bull case is mostly a mid-single-digit compounder story dressed up as a rerating story. If gross profit per script/drug unit normalizes, or if working capital demand rises faster than operating profit, the market will likely cap the forward multiple even with strong EPS growth. The contrarian miss is that “negative equity” is often a non-issue for an asset-light, cash-generative distributor; the real falsifier is not accounting optics, but any evidence that free cash flow conversion or capital return capacity stalls over the next 1-2 quarters.

Time horizon matters: near-term there may be little catalyst beyond earnings and capital-return updates, but over 6-18 months the stock can grind higher if buybacks continue and oncology mix keeps margin stable. If the next two quarters show margin durability and no deterioration in reimbursement/spread dynamics, the market should be forced to re-rate MCK closer to a premium healthcare infrastructure multiple rather than a plain distributor multiple.

Key Decisions for Investors

• Initiate or add to a long MCK position on pullbacks rather than chasing strength; target 10-15% upside over 6-12 months with downside defined by any guide-down in free cash flow conversion or operating margin.
• Use MCK as a defensive healthcare compounder versus broader market exposure: long MCK / short XLY or XLB if you want a lower-beta cash-flow story that should outperform if growth slows and rates stay high over the next 3-6 months.
• Relative-value pair: long MCK / short CAH for a 6-12 month convergence trade if you want the higher-quality balance of growth and capital returns; thesis breaks if CAH closes the execution gap or MCK shows any margin slippage.
• Set an alert for the next two earnings prints: if buybacks/dividend growth continue but free cash flow stalls, trim rather than add; if EPS is up but cash conversion weakens, the rerating case is likely overdone.
• Avoid using options as the base case here unless you need event exposure; the cleaner trade is equity accumulation, since the upside appears gradual and the main risk is thesis decay rather than a binary catalyst.